Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture
Interventions: 10% povidone-iodine (1% free iodine) in purified water, 4% chlorhexidine gluconate (CHG) in purified water; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 1,638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 8 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions: OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo; Drug
Lead sponsor: Oasis Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infection, Advanced End Stage Heart Failure
Interventions: HIV-positive heart transplant; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Concussion, Brain, Concussion Post Syndrome
Interventions: Mindfulness Exercises and Meditations; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 2 Diabetes
Interventions: iCOPE Intervention group; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Cerebellar Ataxia
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Elkins Park, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Healthy
Interventions: [14C]-LY3866288, LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support; Drug · Behavioral
Lead sponsor: City University of New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, HCV
Interventions: Telehealth in Parole/Probation Office; Behavioral
Lead sponsor: Jens Rosenau; Other
Eligibility: 18 Years to 99 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Suicide, Suicide Prevention, Suicide Ideation, Suicide Attempt
Interventions: Caring Connections, Treatment as Usual; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Chronic Pain, Soft Tissue Injuries, Wound Heal, Blood Flow
Interventions: Laser Doppler, Radiofrequency Heating System, Thermal Imaging, Healthcare Questionnaire & Measurement; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Non-adaptive Floreo VR control, Floreo Virtual Reality application; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 16 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus (CMV) Infections
Interventions: V160, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Fountain Valley, California • Orlando, Florida • Burlington, Massachusetts + 1 more

Conditions: Lymphoma, Lymphoid Malignancies
Interventions: ACY-1215; Drug
Lead sponsor: Jennifer Amengual; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions: Vigil, Irinotecan, Temozolomide; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Breast Cancer
Interventions: Cobimetinib, Paclitaxel, Placebo, Atezolizumab, Nab-Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Costa Mesa, California • Plantation, Florida • Indianapolis, Indiana + 4 more

Conditions: Skin Cancer Prevention
Interventions: UV-Detect Photos, Motivational Interviewing, Education; Device · Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 24 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myelogenous Leukemia, AML
Interventions: Venetoclax, Cytarabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Healthy, Frontotemporal Dementia
Interventions: AL001, Placebo; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more

Search by objective public record fields.

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

Mindfulness Intervention in Young Adults With a Concussion History

Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination

Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

A Study of [14C]-LY3866288 in Healthy Participants

Nutrition Intervention Combined With Resmetirom for MASH

Hepatitis C Treatment in Probation and Parole Office

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Caring Connections Youth Suicide Detection and Intervention Study

Radiofrequency Hyperthermia Safety Study

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation